VBL Therapeutics to Report Second Quarter Financial Results on August 16

Rhea-AI Summary

VBL Therapeutics (Nasdaq: VBLT) announced it will release its second-quarter financial results on August 16, 2021, before market open. The results will cover the period ending June 30, 2021, followed by a conference call at 8:30 AM EDT featuring CEO Professor Dror Harats and CFO Amos Ron to discuss the findings. VBL Therapeutics focuses on developing first-in-class treatments for cancer and inflammatory diseases, with its lead candidate VB-111 targeting platinum-resistant ovarian cancer in a Phase 3 trial.

TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am EDT the same day to discuss the results and provide a corporate update.

Conference Call:
Monday, August 16, 2021 at 8:30am EDT
Conference ID: 13721456
US: 1 877 407 9208
Israel Local: 1 809 406 247
International: 1 201 493 6784
Webcast: https://edge.media-server.com/mmc/p/9trg9snq

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a publicly traded (Nasdaq: VBLT), clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune- or inflammatory-related indications. The VBL Therapeutics pipeline has been developed utilizing the company’s three proprietary platform technologies: a gene therapy-based platform technology targeting newly formed blood vessels, an antibody-based technology platform targeting MOSPD2 (motile sperm domain containing 2) and a lecinoxoids platform comprised of a family of small-molecules. The company’s lead oncology candidate, VB-111 (ofranergene obadenovec; `ofra-vec`), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent in development to treat a wide range of solid tumors. VB-111 is currently being studied in a phase 3 potential registration trial for platinum-resistant ovarian cancer.

CONTACT:
Burns McClellan for VBL Therapeutics
Lee Roth & Eric Ando (Investors)
LRoth@burnsmc.com & EAndo@burnsmc.com
+1-212-213-0006

Robert Flamm & Harrison Wong (Media)
RFlamm@burnsmc.com & HWong@burnsmc.com
+1-212-213-0006

FAQ

When will VBL Therapeutics release its Q2 2021 financial results?

VBL Therapeutics will release its Q2 2021 financial results on August 16, 2021, before market open.

What time is the conference call for VBL Therapeutics Q2 2021 results?

The conference call for VBL Therapeutics Q2 2021 results is scheduled for August 16, 2021, at 8:30 AM EDT.

What is the focus of VBL Therapeutics?

VBL Therapeutics focuses on developing first-in-class treatments for cancer and immune or inflammatory-related indications.

What is VBLT's lead oncology candidate?

VBL Therapeutics' lead oncology candidate is VB-111, an investigational anti-cancer gene-therapy agent.

What is the current status of VB-111?

VB-111 is currently being studied in a phase 3 potential registration trial for platinum-resistant ovarian cancer.